Curaleaf (OTCMKTS:CURLF - Get Free Report) had its price objective raised by research analysts at Needham & Company LLC from $5.25 to $6.25 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's price objective would suggest a potential upside of 13.64% from the company's previous close.
Curaleaf Price Performance
OTCMKTS:CURLF remained flat at $5.50 during trading hours on Friday. 910,427 shares of the company's stock traded hands, compared to its average volume of 802,792. Curaleaf has a twelve month low of $2.36 and a twelve month high of $6.40. The firm has a 50-day moving average of $5.07 and a 200 day moving average of $4.51. The company has a debt-to-equity ratio of 0.87, a current ratio of 0.85 and a quick ratio of 0.41.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. Curaleaf had a negative return on equity of 12.93% and a negative net margin of 20.77%. The business had revenue of $345.27 million for the quarter, compared to analysts' expectations of $336.64 million. Research analysts expect that Curaleaf will post -0.18 EPS for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Stories
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
